“Global Limb Reconstruction reported net sales growth of 10% and constant currency growth of 3% compared to the prior year period, reflecting continued demand for core fixation and reconstruction systems.”10-Q · May 5, 2026 ↗
Orthofix Medical Inc.
OFIX
Market read
Orthofix Medical Inc.'s current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 12 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 8 directly disclosed connections are confirming.
- OFIX's market-adjusted activity becomes unusual and at least one connected name confirms.
Invalidation: The isolated read changes if OFIX's group or a disclosed connection begins moving with it.
Research brief
The story so far
No new filing conclusion is available. 0 of 12 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 8 directly disclosed connections are confirming.
No thresholded supportive filing evidence is available yet.
No thresholded adverse filing evidence is available yet.
- OFIX's market-adjusted activity becomes unusual and at least one connected name confirms.
Company research
Understand the business, not just the ticker
Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.
- Which operating variable is changing?
- Is that change durable, cyclical or one-off?
- What evidence would disprove the current interpretation?
- Net margin changed +4.5 percentage points in the latest annual period.
- Demand and volume has repeated favorable evidence across 3 filings.
- Foreign exchange has repeated favorable evidence across 3 filings.
- Diluted shares increased 3.9% in the latest annual period.
No credible peer-relative valuation comparison is available yet.
Price as of Sep 10, 2026
8.69Reported annual revenue and per-share history. This is accounting history, not a forecast.
What management says matters
Persistent and emerging business drivers
“t currency basis, primarily driven by sales of new products launched in the past three years and partially offset by large tender orders in the prior year • Net sales increase of $2.2 million due to movement in foreign currency exchange rates, which had a fav…”10-Q · May 5, 2026 ↗
“Dollars, in thousands) 2026 2025 % Change Research and development $ 15,320 $ 19,766 (22.5 %) As a percentage of net sales 7.8 % 10.2 % (2.4 %) Three months ended March 31, 2026 compared to 2025 Research and development expense decreased $4.4 million • Decrea…”10-Q · May 5, 2026 ↗
“Three months ended March 31, 2026 compared to 2025 Acquisition-related amortization, impairment, and remeasurement decreased $14.0 million • Decrease of $15.4 million in amortization expense primarily associated with the impairment of certain acquired intangi…”10-Q · May 5, 2026 ↗
Valuation discipline
Peer-relative valuation withheld
Jodie found no industry-matched filing peers suitable for a valuation comparison. It will not substitute broader financial-sector names.
Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.
Price action
How the market is pricing the story
Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 11 Sept, 12:45 GMT-4; this is a coverage limitation, not a flat-price conclusion.
Developments
No sourced recent-development timeline yet
Jodie has not returned a relevant primary source or news item for OFIX. This is an evidence-coverage gap, not a conclusion that nothing material happened.
Business and financial condition
Reported financial figures are not available yet
Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.
Filing analysis
No comparable filing assessment is available yet
Jodie has not yet found a suitable current-versus-prior filing comparison for OFIX. This does not mean the latest filing was neutral or immaterial.
Business ecosystem
The relationships behind OFIX
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
HSBCHSBC Holdings plclenderFeb 24, 2026 ▾
“Credit Agreement On November 7, 2024, the Company entered into a $ 275.0 million secured credit agreement (the "Credit Agreement") with Oxford Finance LLC, as administrative agent and as collateral agent ("Oxford") and certain lenders party thereto, including…”
JPMJPMorgan Chase & Co.lenderFeb 24, 2026 ▾
“In November 2023, following the termination of the Second Amended and Restated Credit Agreement with JPMorgan Chase Bank, N.A., as Administrative Agent, and certain lender parties thereto, Bank of America required collateral of approximately $ 4.7 million of…”
Depended on by
GMEDGlobus Medical, Inc.competitorFeb 24, 2026 ▾
“Alphatec Holdings, Orthofix, Integra LifeSciences , ZimVie, Boston Scientific and other smaller public and private companies are also competitors of ours.”
Filing peers
No filing peers are available for this name yet.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 5 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
OFIX is currently a Follower in the organic co-movement group Residential REITs & Insurers. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for OFIX; it is not active in the latest market snapshot.
Context history
Theme membership history
No durable theme membership has been observed for this name yet.